Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Gastrointestinal 2

Conditions

Uterine Cervical Neoplasms 20Papillomavirus Infections 12Uterine Cervical Dysplasia 9Condylomata Acuminata 7Vulvar Neoplasms 4Anus Neoplasms 4Vaginal Neoplasms 3Virus Diseases 1Persistent Infection 1Neoplasms 1Neoplasm Metastasis 1Inflammatory Bowel Diseases 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Crohn Disease 1Colitis, Ulcerative 1Cervical Cancer Screening 1Acquired Immunodeficiency Syndrome 1

Interventions

Radiotherapy 11Brachytherapy 8fludarabine 5Radiation 5Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 5Cyclophosphamide 5aldesleukin 4Surveys and Questionnaires 4Magnetic Resonance Spectroscopy 4Cisplatin 4fludarabine phosphate 3durvalumab 3Vaccines, Synthetic 3Radiosurgery 3Papillomavirus Vaccines 3Paclitaxel 3Methods 3Early Intervention, Educational 33-aminopyridine-2-carboxaldehyde thiosemicarbazone 3tremelimumab 2entinostat 2aflibercept 2Vaccines 2Trastuzumab 2Topotecan 2Therapeutics 2Surgical Procedures, Operative 2Psychiatric Rehabilitation 2Platinum 2Palliative Care 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Vaginal Neoplasms × Papillomavirus Vaccines × Gynecologic × Clear all
NCT06686043 2024-11-13

HPV-VIM

Baylor College of Medicine

Phase 2 Recruiting
85 enrolled
Gynecologic

Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Papillomavirus Infections

NCT05680454 2023-01-17

A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine

Beijing Health Guard Biotechnology, Inc

Phase 1 Completed
160 enrolled
GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT05662020 2022-12-27

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

Beijing Health Guard Biotechnology, Inc

Phase 3 Active not recruiting
2,750 enrolled
GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡